St. Baldrick’s commits $8 million to SU2C Pediatric Cancer Dream Team

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The work of the Stand Up to Cancer-St. Baldrick’s Foundation Pediatric Cancer Dream Team, launched in 2013 to help develop new immunotherapy approaches to high-risk childhood cancers, will continue with a commitment of $8 million from the St. Baldrick’s Foundation, the world’s largest private funder of childhood cancer research grants. To further the impact of this gift, the eight institutions that make up the consortium have committed matching dollars to a total of $16 million.

Continuing as co-leaders of the newly charged St. Baldrick’s-Stand Up to Cancer Pediatric Cancer Dream Team are John Maris, pediatric oncologist and holder of the Giulio D’Angio Chair in Neuroblastoma Research at Children’s Hospital of Philadelphia, and Crystal Mackall, professor of pediatrics (hematology and oncology) at Stanford University and associate director of the Stanford Cancer Institute.

St. Baldrick’s and Stand Up to Cancer initially provided the Dream Team, consisting of more than 150 researchers at eight institutions, with $14.5 million over a four-year term beginning in 2013. The Dream Team worked to improve and expand immunotherapy in childhood cancers.

YOU MAY BE INTERESTED IN

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login